People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Averna Therapeutics Inc. | — | Pharma | Series C | $85.0M | $805.8M | 2024 |
Tal Zaks, M.D., Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tal Zaks, M.D., Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dylan Morris | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Henry Chen | 1 | 7 |
| Michal Silverberg | 1 | 7 |
| Richard Morris | 1 | 4 |
| Tal Zaks | 1 | 3 |
| Nick Olsen | 1 | 2 |
| Anat Nursella | 1 | 1 |
| Alex Harding | 1 | 1 |
| Thomas Barnes | 1 | 1 |
| Roy Amariglio | 1 | 1 |
| Raju Prasad | 1 | 1 |
| Raju Prasad, Ph.D. | 1 | 1 |
| Thomas Barnes, Ph.D. | 1 | 1 |
| Aaron Nelson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.